{"doi":"10.1111/bcp.15862","title":"Non‐compartmental and population pharmacokinetic analysis of dapsone in healthy NIGERIANS: A pilot study","abstract":"Abstract Dapsone is employed for both non‐dermatological and dermatological indications but with non‐existent population pharmacokinetics (popPK) data in Nigerians. This study was therefore designed to develop a popPK model in Nigerians. Non‐compartmental analysis and nonlinear mixed effects modelling were utilized for data analysis. Eleven participants administered 50 mg dapsone tablet were included in the analysis. Derived pharmacokinetic parameters were: C max = 1.16 ± 0.32 μg/mL, T max = 3.77 ± 2.40 h, and t 1/2z = 30.23 ± 11.76 h. PopPK model parameter estimates with inter‐individual variability were Tlag = 0.40 h (10.0%, fixed); k a = 1.78 h −1 (75.9%); V/F = 89.25 L (21.6%); and Cl/F = 1.32 Lh −1 (27.7%). Sex was significantly associated with Cl / F, and body weight with V/F. Best popPK model was one‐compartment with lag time, and first‐order absorption and elimination. Sex and body weight significantly influenced the clearance and distribution volume of dapsone respectively.","journal":"British Journal of Clinical Pharmacology","year":2023,"id":356655,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":3,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.8225,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1105722,"name":"David Taiwo Ajayi","orcid":"0000-0001-7610-0735","position":1,"is_corresponding":false},{"id":940952,"name":"Collen Masimirembwa","orcid":"0000-0002-4053-212X","position":2,"is_corresponding":false},{"id":940950,"name":"Roslyn Thelingwani","orcid":"0000-0001-8396-6609","position":3,"is_corresponding":false},{"id":571689,"name":"Abayomi Odetunde","orcid":"0000-0001-6513-1165","position":4,"is_corresponding":false},{"id":453017,"name":"Adeyinka G. Falusi","orcid":"0000-0002-3064-3336","position":5,"is_corresponding":false},{"id":363297,"name":"Chinedum P. Babalola","orcid":"0000-0001-9173-8032","position":6,"is_corresponding":false},{"id":363296,"name":"Olayinka Kotila","orcid":"0000-0002-0674-9085","position":0,"is_corresponding":true}],"reference_count":25,"raw_metadata":null,"created_at":"2026-07-19T01:13:30.556819Z","pmid":"37489004","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}